Findings

What do systematic reviews say?

8 questions · 8 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 3 · 37.5%Low 1 · 12.5%Moderate 2 · 25%High 0 · 0%

Low molecular weight heparin vs no prophylaxis

Minor bleeding · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.79 [0.84, 3.84]
5 studies · 1978 participants
Moderate

Low molecular weight heparin vs unfractionated heparin

Minor bleeding · adults with kidney failure treated with long‐term HD

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs control

Minor bleeding · children with a CVC

1 finding from 1 review

Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 813 participants
Very low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.95 [0.2, 4.61]
1 study · 234 participants
Very low

Low molecular weight heparin vs no LMWH

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.35 [0.62, 2.92]
2 studies · 544 participants
Low

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.85 [0.95, 3.59]
5 studies · 1978 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.78 [0.47, 1.27]
4 studies · 1712 participants
Very low